Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig in Relapsed or Refractory Ewing Sarcoma
NCT07297979Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- May 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 1, open-label trial of xaluritamig in Ewing sarcoma (2 arms), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicity up to 42 days and Treatment-emergent Adverse Events. Started Apr 2026; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT07297979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297979.